Florida / New York

Ph: 561.316.3330

A Publication for the Practicing Medical Specialist, Industry Executive & Investor

BIOTECHNOLOGY

Medical Device News Magazine reports breaking biotechnology news including new biotech developments, pharmaceuticals and more.

Rejuvenate Biomed and SAS Tap AI to Develop Disease-agnostic Drug Repurposing Discovery Tools

“Our partnership with SAS amplifies the core strengths of both our R&D teams,” Dr. Ann Beliën, Founder and Chief Executive Officer of Rejuvenate Biomed. “By embracing this partnership and leveraging the capabilities of SAS Viya, we expect to meaningfully de-risk and accelerate the development of our internal portfolio while enhancing our discovery platform and partnering capabilities.”

Read More »

Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class

“For the first time, we are able to imagine and generate chemically synthesized biologics at scale and with increasing programmability, offering a new class of medicines with transformative potential,” said Avak Kahvejian, Ph.D., Co-Founder and CEO of Abiologics and General Partner at Flagship Pioneering. “Creating protein biologics with artificial building blocks rather than naturally occurring amino acids allows Synteins to go unrecognized by the immune system, offering significant advantages compared to today’s biologics such as less frequent dosing, oral delivery and the ability to reach parts of the body that were previously impossible to access and treat. With Synteins, Abiologics is poised to bring boundary-breaking medicines to patients across a range of diseases.”

Read More »

Biolyst Scientific Announces New Brand Name to Encompass EMS and Azer | Will Deepen Offerings to Clinical and Research Lab Customers

The new name, ‘Biolyst,’ reflects the essential part the company plays in the Life Sciences discoveries that make life better for all. ‘Bio’ signals where impact is felt – in enhancing and extending life – and ‘lyst’ signifies its role as catalyst in helping clinical and research labs pursue breakthroughs with accuracy and efficiency. The EMS and Azer brand names will continue to exist as ‘power brands’ within the product portfolio.

Read More »

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Razi Ingber, RedHill Biopharma and Chief Financial Officer, said: “We are very pleased to reach this smooth conclusion, which strengthens RedHill’s cash position and greatly enhances our ability to manage our cash. The Agreement eliminates substantially all encumbrances related to the previous Movantik divestment and Credit Agreements, allowing us to better focus on our R&D and commercial activities and return the Company to a growth mode. This is a new chapter for RedHill.”

Read More »